JPMORGAN CHASE & CO - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 80 filers reported holding LYELL IMMUNOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.02 and the average weighting 1.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$374,057
-50.0%
254,461
+8.1%
0.00%
Q2 2023$748,493
-49.3%
235,375
-62.3%
0.00%
Q1 2023$1,475,000
+74207.3%
625,007
+9.2%
0.00%
Q4 2022$1,985
-99.9%
572,147
+10.0%
0.00%
-100.0%
Q3 2022$3,812,000
+10.9%
519,992
-1.4%
0.00%
Q2 2022$3,437,000
+31.3%
527,174
+1.7%
0.00%
Q1 2022$2,618,000
-27.2%
518,404
+11.6%
0.00%
Q4 2021$3,594,000
-29.0%
464,351
+35.7%
0.00%
-100.0%
Q3 2021$5,063,000342,0720.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders